Table 3.
Characteristics of the patients with CSVD in CDR 0, 0.5, and 1–2
| Score | CDR 0 (N = 27) | CDR 0.5 (N = 48) | CDR 1–2 (N = 83) | p value | |
|---|---|---|---|---|---|
| CSVD, n (%) | 0 | 20 (74.07%) | 30 (62.50%) | 25 (30.12%) | < 0.001 |
| 1 | 6 (22.22%) | 8 (16.67%) | 25 (30.12%) | ||
| ≥ 2 | 1 (3.70%) | 10 (20.83%) | 33 (39.76%) | ||
| PVWMH, n (%) | 0 | 22 (81.48%) | 24 (50.00%) | 26 (31.33%) | < 0.001 |
| 1 | 5 (18.52%) | 17 (35.42%) | 29 (34.94%) | ||
| 2 | 0 (0.00%) | 6 (12.50%) | 22 (26.51%) | ||
| 3 | 0 (0.00%) | 1 (2.08%) | 6 (7.23%) | ||
| DWMH, n (%) | 0 | 23 (85.19%) | 30 (62.50%) | 42 (50.60%) | 0.035 |
| 1 | 4 (14.81%) | 17 (35.42%) | 32 (38.55%) | ||
| 2 | 0 (0.00%) | 1 (2.08%) | 6 (7.23%) | ||
| 3 | 0 (0.00%) | 0 (0.00%) | 3 (3.61%) | ||
| CMBn, median (IQR) | 0 ± 0 | 0 ± 0 | 0 ± 4 | 0.028 |
p < 0.05 was considered statistically significant.
PVWMHs periventricular spaces white matter hyperintensity Fazekas score, DWMHs deep spaces white matter hyperintensity Fazekas score, CMBn cerebral microbleeds numbers